Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

March 4, 2021

Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

February 17, 2021

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

January 13, 2021

Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

January 11, 2021

Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

January 6, 2021

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

January 6, 2021

Harpoon Therapeutics Announces Proposed Public Offering of Common Stock

January 4, 2021

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

December 8, 2020

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

December 7, 2020

Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

November 16, 2020

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2021. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations